表紙
市場調查報告書

伽馬-胺基丁酸受體次單元伽馬2:開發中產品分析

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 556451
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
伽馬-胺基丁酸受體次單元伽馬2:開發中產品分析 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 53 Pages
簡介

這份報告提供以伽馬-胺基丁酸受體次單元伽馬2為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

伽馬-胺基丁酸受體次單元伽馬2;概要

伽馬-胺基丁酸受體次單元伽馬2;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Paion AG
  • Pfizer Inc
  • Primex Pharmaceuticals Oy
  • Shire Plc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2058TDB

Summary

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019'; Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular responses to histamine. It functions as receptor for diazepines and various anesthetics and as ligand-gated chloride channel.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Sedation, General Anesthetic Effect, Hypercholesterolemia, Status Epilepticus and Substance (Drug) Abuse.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
  • The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Overview
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Companies Involved in Therapeutics Development
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Paion AG
  • Takeda Pharmaceutical Co Ltd
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Drug Profiles
  • clonazepam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EL-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HR-7056 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LASSBio-785 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • midazolam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Dormant Products
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Discontinued Products
  • Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency
  • Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement
  • Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia
  • Jun 10, 2019: FDA accepts filing of NDA for Remimazolam
  • Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA
  • Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial
  • Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea
  • Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia
  • May 17, 2018: Paion announces clinical development progress with Remimazolam by its partner R-Pharm in Russia
  • Jan 15, 2018: European Medicines Agency: Defect with Buccolam oral syringes
  • Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera
  • Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required
  • Oct 19, 2017: Paion to host remimazolam Symposium at Japan Society for Clinical Anesthesia annual meeting in Japan
  • Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented at the Chest Annual Meeting 2017
  • Oct 13, 2017: Japan Patent Office grants dosing Patent for Remimazolam in Japan
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2019
  • Pipeline by Paion AG, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top